Impressive Boosting of Anti-S1/S2 Immunoglobulin G Production in Coronavirus Disease 2019 (COVID-19)-experienced Patients After the First Shot of the BNT162b2 Messenger RNA COVID-19 Vaccine.

Authors	Amedeo F Capetti, Carlo A Stangalini, Fabio Borgonovo, Davide Mileto, Letizia Oreni, Gianfranco Dedivitiis, Angelica Lupo, Maria V Cossu, Lara Bilardo, Andrea Giacomelli, Massimo Galli, Giuliano Rizzardini
Journal	Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (Clin Infect Dis) Vol. 73 Issue 6 Pg. e1402-e1403 (09 15 2021) ISSN: 1537-6591 [Electronic] United States
PMID	33693610 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References	COVID-19 Vaccines Immunoglobulin G RNA, Messenger BNT162 Vaccine
Topics	BNT162 Vaccine COVID-19 COVID-19 Vaccines Humans Immunoglobulin G RNA, Messenger SARS-CoV-2

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!